Because tau hyperphosphorylation has been associated with major neurodegenerative diseases, including Alzheimer's disease, NAP holds promise as a neuroprotective/neurotropic drug candidate. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.